{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04800692",
            "orgStudyIdInfo": {
                "id": "H00012734"
            },
            "organization": {
                "fullName": "University of Massachusetts, Worcester",
                "class": "OTHER"
            },
            "briefTitle": "The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication",
            "officialTitle": "The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication",
            "acronym": "ATLAS",
            "therapeuticArea": [
                "Other"
            ],
            "study": "the-effects-of-atlas-therapy-on-nitric-oxide-bioavailability-in-patients-with-intermittent-claudication"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-03-11",
            "studyFirstSubmitQcDate": "2021-03-11",
            "studyFirstPostDateStruct": {
                "date": "2021-03-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-14",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Louis Messina",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Massachusetts, Worcester"
            },
            "leadSponsor": {
                "name": "Louis Messina",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "BioMarin Pharmaceutical",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This study will focus on people with claudication from peripheral arterial disease. The investigators are researching whether a multicomponent therapeutic can increase the production of Nitric Oxide in the blood and whether that leads to an improvement in pain free walking distance and overall physical activity.",
            "detailedDescription": "The primary objective of this study is to show that ATLAS Therapy, (L-Arginine; Tetrahydrobiopterin; L-Ascorbate) is bioavailable in humans and exerts a measurable effect on its in vivo biological signature, Flow Mediated Vasodilation (FMD) in people with intermittent claudication caused by peripheral arterial disease. This will be a Phase I / dose finding study. All subjects will receive 2 different drug doses of the Kuvan the first 45 days they will receive 10 mg/kg/day. The second 45 days they will receive 20/mg/kg/day."
        },
        "conditionsModule": {
            "conditions": [
                "Claudication, Intermittent",
                "Peripheral Artery Disease",
                "Peripheral Vascular Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "All subjects will receive the same starting dose of the 3 components which will be escalated at day 45.",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Tetrahydrobiopterin Dose 1 (Day 0 to 44)",
                    "type": "EXPERIMENTAL",
                    "description": "All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.",
                    "interventionNames": [
                        "Drug: Tetrahydrobiopterin 10 mg/kg",
                        "Drug: L-Ascorbate",
                        "Drug: L-Arginine"
                    ]
                },
                {
                    "label": "Tetrahydrobiopterin Dose 2 (Day 45 to 90)",
                    "type": "EXPERIMENTAL",
                    "description": "All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.",
                    "interventionNames": [
                        "Drug: Tetrahydrobiopterin 20 mg/kg",
                        "Drug: L-Ascorbate",
                        "Drug: L-Arginine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tetrahydrobiopterin 10 mg/kg",
                    "description": "10mg/kg of Tetrahydrobiopterin daily.",
                    "armGroupLabels": [
                        "Tetrahydrobiopterin Dose 1 (Day 0 to 44)"
                    ],
                    "otherNames": [
                        "sapropterin",
                        "kuvan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tetrahydrobiopterin 20 mg/kg",
                    "description": "20mg/kg of Tetrahydrobiopterin daily.",
                    "armGroupLabels": [
                        "Tetrahydrobiopterin Dose 2 (Day 45 to 90)"
                    ],
                    "otherNames": [
                        "sapropterin",
                        "kuvan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "L-Ascorbate",
                    "description": "3300 mg of l-ascorbate once daily",
                    "armGroupLabels": [
                        "Tetrahydrobiopterin Dose 1 (Day 0 to 44)",
                        "Tetrahydrobiopterin Dose 2 (Day 45 to 90)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "L-Arginine",
                    "description": "3400mg of l-arginine once daily",
                    "armGroupLabels": [
                        "Tetrahydrobiopterin Dose 1 (Day 0 to 44)",
                        "Tetrahydrobiopterin Dose 2 (Day 45 to 90)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Nitric Oxide bioavailability",
                    "description": "Nitric Oxide bioavailability as measured by flow mediated dilatation (FMD).",
                    "timeFrame": "90 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* PAD as demonstrated by an ABI \\<0 .9 in one leg or TBI less than \\<0.7 in patients with an ABI \\>1.3 (non compressible vessels)\n* Rutherford Classification II, III\n* Age \\>18 years old\n* Willingness to discontinue phosphodiesterase (PDE) 5 inhibitors such as Viagra, Cialis, Levitra, Revatio\n* Willingness to discontinue phosphodiesterase (PDE) 3inhibitors cilostazol, milrinone or Vesnarinone\n* Willing and able to comply with all study procedures\n* Willing and able to provide informed consent\n* Sexually active subjects willing to use an acceptable method of contraception while participating in the study\n\nExclusion Criteria:\n\n* Hypotension defined as a systolic blood pressure less than 100mmhg systolic at screening or baseline visit\n* Critical Leg Ischemia (Rutherford Classification IV, V, VI)\n* Surgical intervention to alleviate symptoms of claudication in the study leg within the past 6 months or any endovascular interventions within 3 months or who is scheduled to undergo surgical revascularization in the next 6 month\n* Walking limited by reasons other than claudication (e.g. arthritis, lung disease, severe neuropathy, lower extremity amputation except single digits)\n* Serum creatinine \\>1.5mg/dl or Hepatic enzymes \\>2X the upper limit of normal\n* Serum potassium greater than 5.0 or use of a potassium sparing diuretic at screening\n* Pregnant, breast feeding or planning to become pregnant (subject or partner) at any time during the study.\n* Myocardial Infarction, Cerebrovascular Accident or deep vein thrombosis within 12 months of screening\n* Known history of nephrolithiasis\n* History of ever having a seizure\n* Concurrent disease or condition that would interfere with study participation or safety such as bleeding disorders, organ transplant, long term immunosuppression (excluding inhaled steroids), current neoplasm or severe gastroesophageal reflux\n* History of vertigo or syncope within the past 10 years\n* Enrollment in another drug or device study within 30 days of screening\n* Required treatment with a drug known to inhibit folate metabolism (e.g. Methotrexate)\n* Taking any of the following medications; PDE3 Inhibitors, PDE5 inhibitors, trental, nitrates, ginkgo biloba, levodopa, warfarin,\n* Axillary lymph node dissection\n* Presence of an amputation except single digits in either leg\n* Preexisting illness that limits ambulation such as severe COPD, class III-IV heart failure, severe arthritis or back pain\n* Glucose-6-dehydrogenase deficiency",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Shauneen Valliere, MSN",
                    "role": "CONTACT",
                    "phone": "508-856-1767",
                    "email": "shauneen.valliere@umassmed.edu"
                },
                {
                    "name": "Mollynda McArthur, MS",
                    "role": "CONTACT",
                    "phone": "508-856-2820",
                    "email": "mollynda.mcarthur2@umassmed.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Louis M Messina, MD",
                    "affiliation": "UMASS Medical School",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "UMASS Memorial Healthcare - University Campus",
                    "status": "RECRUITING",
                    "city": "Worcester",
                    "state": "Massachusetts",
                    "zip": "01655",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shauneen Valliere, MSN",
                            "role": "CONTACT",
                            "phone": "508-856-1767",
                            "email": "shauneen.valliere@umassmed.edu"
                        },
                        {
                            "name": "Mollynda McArthur, MS",
                            "role": "CONTACT",
                            "phone": "508-856-2820",
                            "email": "mollynda.mcarthur2@umassmed.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.26259,
                        "lon": -71.80229
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000058729",
                    "term": "Peripheral Arterial Disease"
                },
                {
                    "id": "D000007383",
                    "term": "Intermittent Claudication"
                },
                {
                    "id": "D000016491",
                    "term": "Peripheral Vascular Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000050197",
                    "term": "Atherosclerosis"
                },
                {
                    "id": "D000001161",
                    "term": "Arteriosclerosis"
                },
                {
                    "id": "D000001157",
                    "term": "Arterial Occlusive Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M29213",
                    "name": "Peripheral Arterial Disease",
                    "asFound": "Peripheral Artery Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18894",
                    "name": "Peripheral Vascular Diseases",
                    "asFound": "Peripheral Vascular Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "asFound": "Vascular Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10418",
                    "name": "Intermittent Claudication",
                    "asFound": "Claudication",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26188",
                    "name": "Atherosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4469",
                    "name": "Arteriosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4465",
                    "name": "Arterial Occlusive Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014700",
                    "term": "Verapamil"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000889",
                    "term": "Anti-Arrhythmia Agents"
                },
                {
                    "id": "D000002121",
                    "term": "Calcium Channel Blockers"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000077264",
                    "term": "Calcium-Regulating Hormones and Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000014665",
                    "term": "Vasodilator Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12507",
                    "name": "Nitric Oxide",
                    "relevance": "LOW"
                },
                {
                    "id": "M17446",
                    "name": "Verapamil",
                    "asFound": "Spleen",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4213",
                    "name": "Anti-Arrhythmia Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M5384",
                    "name": "Calcium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M17412",
                    "name": "Vasodilator Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T1",
                    "name": "Arginine",
                    "asFound": "Healthy controls",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}